Recent News

• 08.07.2026 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.06.2026 - Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
• 08.04.2026 - Pacira BioSciences Reports Second Quarter 2026 Financial Results
• 07.28.2026 - Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
• 07.27.2026 - Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
• 07.22.2026 - Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
• 07.08.2026 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.01.2026 - Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
• 06.30.2026 - Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
• 05.28.2026 - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees

Recent Filings

• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.04.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1
• 06.30.2026 - EX-99.1 EX-99.1
• 06.30.2026 - 8-K Current report
• 06.12.2026 - 3 Initial statement of beneficial ownership of securities
• 06.12.2026 - 144 Report of proposed sale of securities
• 06.12.2026 - 4 Statement of changes in beneficial ownership of securities